ClinicalTrials.gg
RecruitingNCT05945732Updated Aug 19, 2026

DESTINY Breast Respond HER2-(Ultra)Low Europe

An observational study in Unresectable Breast Cancer, Metastatic Breast Cancer and HER2-low Expressing Breast Cancer, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Recruiting at 216 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,295
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Breast Neoplasms by Daiichi Sankyo — 6 open to participants now, 8 under way, 3 of them phase 3. Breast Neoplasms · Daiichi Sankyo.

Started
2023
with 3 others
Observational
8 of 24
2 open now
Registered
17th of 24
by date

Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is one of 4 that started in 2023, is one of 8 observational ones, and was the 17th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 24 studies in Breast Neoplasms by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Daiichi Sankyo, or all of them as a file.
02

Study summary

Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.

Read the detailed description

This non-interventional study will investigate the effectiveness of T-DXd, the demographic and clinical characteristics of the patients, treatment patterns, tolerability, management of adverse drug reactions (ADRs), and patient experience of T-DXd in patients with HER2-low and HER2-(ultra)low unresectable and/or metastatic breast cancer. Patients will be treated according to the proposed indication statement in the Summary of Product Characteristics (SmPC). No drug product will be administered as part of this study.

Data on conventional chemotherapy (i.e., including but not limited to capecitabine, eribulin, gemcitabine, paclitaxel and nab-paclitaxel) will also be collected in a disease registry part of the study. For Study Group 2, only baseline data will be collected for patients treated with conventional chemotherapy.

03

Conditions studied

  • Unresectable Breast Cancer
  • Metastatic Breast Cancer
  • HER2-low Expressing Breast Cancer
  • HER2-(Ultra)Low Expressing Breast Cancer

Browse trials for

Keywords

  • Unresectable Breast Cancer
  • Metastatic Breast Cancer
  • HER2-low Expressing Breast Cancer
  • Trastuzumab Deruxtecan
  • Enhertu®
  • HER2-(ultra)low Expressing Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study Group 1 will include adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Study Group 2 will include adult patients with unresectable or metastatic HR +, HER2-low and HER2- ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment and have not received prior chemotherapy for advanced metastatic breast cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study Group 1 and Study Group 2

  • Adult patient (age ≥ 18 years) with histological or cytological confirmed diagnosis of unresectable and/or mBC
  • Decision to newly initiate therapy of T-DXd or conventional chemotherapy according to the physicians choice per SmPC
  • Written and signed to participate in the study

Study Group 1

  • Documented -low status (IHC1+, IHC2+/ISH-)
  • Patients who have received prior chemotherapy in the setting or
  • Patients who have developed disease recurrence during or within 6 months of completing chemotherapy

Study Group 2:

  • Documented HR+ status
  • Documented HER2-low status (IHC1+ or IHC2+/ISH-) or HER2-ultralow (defined as IHC 0 with membrane staining [IHC > 0 to \<1+]) status
  • Patients who have received at least one endocrine therapy in the metastatic setting
  • Patients who have NOT received prior chemotherapy in the metastatic setting

Exclusion criteria

Exclusion Criteria:

Study Group 1 and Study Group 2

  • Pregnancy or breastfeeding
  • Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.

No other specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,295 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Group 1

    Adult participants with 2L+ HER2-low expressing unresectable and/or metastatic breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. In addition, patients with HER2-low breast cancer treated with conventional chemotherapy will be enrolled. The participants on conventional chemotherapy will be analyzed as exploratory only.

    Drug: Trastuzumab deruxtecan

  • Study Group 2

    Adult participants in the first-line setting with hormone receptor (HR) positive, HER2-low or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment and have not received prior chemotherapy for advanced metastatic breast cancer.

    Drug: Trastuzumab deruxtecan

Interventions

  • This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. Trastuzumab (T-DXd) to be administered according to the SmPC. Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.

    Also known as: T-DXd

06

What researchers measure

Primary outcomes

  1. Real World Time to Next Treatment (rwTTNT1) in Participants With Unresectable and/or Metastatic Breast Cancer

    Time frame: Baseline up to approximately 37 months

Secondary outcomes

  1. Type of Treatment Patterns in Participants With Unresectable and/or Metastatic Breast Cancer

    Time frame: Baseline up to approximately 37 months

  2. Number of Physician-reported Safety Events of Interest in Participants With Unresectable and/or Metastatic Breast Cancer (T-DXd only)

    Time frame: Baseline up to approximately 37 months

  3. Number of Participants Receiving Prophylactic and Reactive Treatment Management for Physician-reported Safety Events of Interest in Participants With Unresectable and/or Metastatic Breast Cancer (T-DXd only)

    Time frame: Baseline up to approximately 37 months

  4. Real World Time to Permanent Treatment Discontinuation (rwTTD1) in Participants With Unresectable and/or Metastatic Breast Cancer

    Time frame: Baseline up to approximately 37 months

  5. Patient's Global Impression of Treatment Tolerability (PGI-TT) in Participants With Unresectable and/or Metastatic Breast Cancer

    The PGI-TT is designed to assess the treatment tolerability of the medicine. Participants will rate the bother associated with any treatment-related symptoms based on a 5-point scale ranging from 1 (not at all) to 5 (very much). Higher scores indicate a worse outcome.

    Time frame: Baseline up to approximately 37 months

  6. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score in Participants With Unresectable and/or Metastatic Breast Cancer

    The EORTC QLQ-C30 questionnaire is designed to measure cancer patients' physical, psychological and social functions. The EORTC QLQ-C30 scales and single-item scales range in score from 0 to 100. A higher score for the functioning scales and global health status denotes a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient).

    Time frame: Baseline up to approximately 37 months

  7. Number of Participants Reporting Nausea and Vomiting as Assessed by a Patient Diary

    Time frame: Baseline up to approximately 37 months

07

Study locations

26 of 216 sites recruiting
  • Medizinische Universität Graz
    Graz, 8036, Austria
    Terminated

    Not enrolling at this site — choose another above.

  • Medizinische Universität Graz
    Graz, 8036, Austria
    Recruiting
    • Principal Investigator · Contact
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
    Recruiting
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
    Recruiting
    • Principal Investigator · Contact
  • LKH Hochsteiermark-Leoben
    Leoben, 8700, Austria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ordensklinikum Linz GmbH Barmherzige Schwestern
    Linz, 4010, Austria
    Recruiting
    • Principal Investigator · Contact
  • Interne II, LKH Feldkirch
    Rankweil, 6830, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • KH der Barmherzigen Brüder Salzburg
    Salzburg, 5010, Austria
    Recruiting
    • Principal Investigator · Contact
  • Uniklinikum Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Principal Investigator · Contact
  • Medical University of Vienna
    Vienna, 1090, Austria
    Recruiting
    • Principal Investigator · Contact
  • Medizinische Universität Wien
    Vienna, 1090, Austria
    Terminated

    Not enrolling at this site — choose another above.

  • Krankenhaus Hietzing
    Vienna, 1130, Austria
    Recruiting
    • Principal Investigator · Contact
  • Salzkammergut Klinikum Vöcklabruck
    Vöcklabruck, 4840, Austria
    Recruiting
    • Principal Investigator · Contact
  • Klinikum Wels-Grieskirchen GmbH
    Wels, 4600, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Landesklinikum Wiener Neustadt
    Wiener Neustadt, 2700, Austria
    Recruiting
    • Principal Investigator · Contact
  • ASZ Aalst
    Aalst, 9300, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chirec Delta Hospital
    Auderghem, 1160, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Imeldaziekenhuis Bonheiden
    Bonheiden, 2820, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AZ Klina
    Brasschaat, 2930, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AZ Sint-Jan Brugge av
    Bruges, 8000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Brugmann
    Brussels, 1020, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chu Helora- Hôpital de La Louvière- site Jolimont
    Haine-Saint-Paul, 7100, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Tivoli
    La Louvière, 7100, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHC MontLegia
    Liège, 4000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital de la Citadelle
    Liège, 4000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU UCL Namur/Site Sainte Elisabeth
    Namur, B5000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique Saint Pierre Ottignies
    Ottignies, 1340, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • VITAZ
    Sint-Niklaas, 9100, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHR Verviers East Belgium
    Verviers, 4800, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Aalborg Universitetshospital, Syd
    Aalborg, 9000, Denmark
    Terminated

    Not enrolling at this site — choose another above.

  • Aarhus University Hospital
    Aarhus N, 8200, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Herlev Hospital
    Herlev, 2730, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Onkologisk og Palliativ afdeling, Nordsjællands Hospital
    Hillerød, 3400, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Naestved Hospital
    Næstved, 4700, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sygehus Sønderjylland, Sønderborg
    Sønderborg, 6400, Denmark
    Terminated

    Not enrolling at this site — choose another above.

  • CHU Amiens Picardie
    Amiens, 80000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique de l'Europe
    Amiens, 80090, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Privé d'Antony
    Antony, 92160, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hôpital Privé les Bonnettes
    Arras, 62000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut du Cancer Avignon Provence
    Avignon, 84918, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CH Cote Basque
    Bayonne, 64100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique Belharra
    Bayonne, 64100, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Chu Jean Minjoz Besancon
    Besançon, 25000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique Tivoli-Ducos
    Bordeaux, 33000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre hospitalier Fleyriat
    Bourg-en-Bresse, 01012, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Francois Baclesse
    Caen, 14000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier William Morey
    Chalon-sur-Saône, 71321, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CH Metropole Savoie
    Chambéry, 73000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pole Sante Leonard De Vinci
    Chambray-lès-Tours, 37170, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CH Cholet
    Cholet, 49300, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Polyclinique St Côme
    Compiègne, 60200, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Henri Mondor
    Créteil, 94000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Léonard de Vinci
    Dechy, 59187, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Georges Francois Leclerc
    Dijon, 21000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Martinique
    Fort de France Cedex, 97261, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHI Frejus Saint Raphael
    Fréjus, 83600, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Groupe Hospitalier Mutualiste (GHM) de Grenoble - Institut Daniel Hollard (IDH)
    Grenoble, 38000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Polyclinique De Blois
    La Chaussée-Saint-Victor, 41260, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • La Tronche - CHU Grenoble
    La Tronche, 38700, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre de cancerologie de la Sarthe
    Le Mans, 72100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Emile Roux
    Le Puy-en-Velay, 43000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Franco-Britannique Cognac Jay
    Levallois-Perret, 92300, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Oscar Lambret
    Lille, 59000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Lille
    Lille, 59000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Prive Le Bois
    Lille, 59000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de Limoges
    Limoges, 87042, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospices Civils De Lyon
    Lyon, 69002, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Jean Mermoz
    Lyon, 69008, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital-Clinique Claude Bernard
    Metz, 57070, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • GH Havre
    Montivilliers, 76920, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique Clementville
    Montpellier, 34070, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Groupe Hospitalier privé Ambroise Pare Hartmann
    Neuilly-sur-Seine, 92200, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hopital Americain de Paris
    Neuilly-sur-Seine, 92200, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Antoine Lacassagne
    Nice, 06100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de Niort
    Niort, 79000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Médical ONCOGARD
    Nîmes, 30029, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Curie
    Paris, 75005, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Groupement Hospitalier Diaconesses Croix Saint Simon
    Paris, 75012, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hopital Europeen Georges Pompidou
    Paris, 75015, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Saint Joseph
    Paris, 75103, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de Pau
    Pau, 64000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Poitiers
    Poitiers, 86000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Godinot
    Reims, 51100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Polyclinique Courlancy
    Reims, 51100, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Eugene Marquis
    Rennes, 35042, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinique Saint Hilaire
    Rouen, 76000, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinique Mathilde
    Rouen, 76100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Saint Cloud -Rene Huguenin Institut Curie
    Saint-Cloud, 92210, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • CHU Réunion Site Sud
    Saint-Paul, 97460, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut De Cancerologie Paris Nord
    Sarcelles, 95200, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de Sens
    Sens Cédex, 89108, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Foch
    Suresnes, 92150, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHR Metz Thionville
    Thionville, 57100, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HIA Sainte-Anne
    Toulon, 83000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de Troyes
    Troyes, 10000, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hopital Prive Drome Ardeche
    Valence, 26000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nouvelle Clinique Des Dentellières
    Valenciennes, 59300, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 216 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Guarneri V, Passos Coelho JL, Duhoux FP, Egle D, Garcia-Saenz JA, Penault-Llorca F, Selander K, Wildiers H, Zaman K, Laeis P, Lucerna M, Pierga JY. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Future Oncol. 2024;20(18):1237-1250. doi: 10.2217/fon-2024-0015. Epub 2024 Apr 9. PubMed 38592002 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2030, 86 months after the start.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 86 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jul 14, 2023
StartActual
Oct 24, 2023
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05945732
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Oct 24, 2023
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 19, 2026

Study contacts

Contact for Clinical Trial Information
Contact
CTRinfo@dsi.com
908-992-6400
Global Team Leader
study director · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion